The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Sanofi (Inst)
 
Jean-Yves Blay
Consulting or Advisory Role - GlaxoSmithKline; Novartis; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; PharmaMar; Roche
Travel, Accommodations, Expenses - GlaxoSmithKline; Novartis; PharmaMar; Roche
 
Aurelien Marabelle
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Flexus Biosciences; Imaxio; Pfizer; Roche
 
David Stanbury
Employment - Emas pharma
 
Satvinder Mudan
Leadership - Immodulon Therapeutics
Stock and Other Ownership Interests - Immodulon Therapeutics
 
Laura Rosa Brunet
Employment - Immodulon Therapeutics
Patents, Royalties, Other Intellectual Property - Immodulon Therapeutics